Efficacy of Hedgehog pathway inhibitors in basal cell carcinoma

Molecular Cancer Therapeutics

Volumn 14, Issue 3, 2015, Pages 633-641

  Basset Seguin, Nicole ^a,b   Sharpe, Hayley J ^b   De Sauvage, Frederic J ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 833923; GLASDEGIB; PROTEIN INHIBITOR; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; SONIDEGIB; TALADEGIB; VISMODEGIB; ANTINEOPLASTIC AGENT;

ANIMAL MODEL; BASAL CELL CARCINOMA; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; INCIDENCE; METASTASIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, BASAL CELL; DRUG EFFECTS; METABOLISM; SKIN NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; HEDGEHOG PROTEINS; HUMANS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84934345626     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0703     Document Type: Review

References (76)

1. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005;353:2262-9.
2. Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E, Abeni D. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparabledata are neededfor effective public health monitoring and interventions. Br J Dermatol 2007;156 Suppl 3:1-7.
3. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994;30:774-8.
4. Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 2006;184:6-10.
5. Trakatelli M, Morton C, Nagore E, Ulrich C, Del Marmol V, Peris K, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol 2014;24:312-29.
6. Guthrie TH, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal cell carcinoma and squamous cell carcinoma of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 1990;8:342-6.
7. Snow SN, Sahl W, Lo JS, Mohs FE, Warner T, Dekkinga JA, et al. Metastatic basal cell carcinoma. Report of five cases. Cancer 1994;73:328-35.
8. Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004;23:389-402.
9. McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer 2014;50:774-83.
10. Briscoe J, Therond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol 2013;14:416-29.
11. Goetz SC, Anderson KV. The primary cilium: a signalling centre during vertebrate development. Nat Rev Genet 2010;11:331-44.
12. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391:90-2.
13. Reifenberger J, Wolter M, Knobbe CB, Kohler B, Schonicke A, Scharwachter C, et al. Somatic mutationsinthe PTCH, SMOH, SUFUH and TP53genes in sporadic basal cell carcinomas. Br J Dermatol 2005;152:43-51.
14. Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol 2014;134:213-20.
15. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996;272:1668-71.
16. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996;85: 841-51.
17. Raffel C, Jenkins RB, Frederick L, Hebrink D, Alderete B, Fults DW, et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997; 57:842-5.
18. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488:43-8.
19. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013;45:285-9.
20. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013;339:1077-80.
21. Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA, et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet 2014;46:722-5.
22. Rubin LL, de Sauvage FJ. Targeting the hedgehog pathway in cancer. Nat Rev Cancer 2006;5:1026-33.
23. Ng JM, Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer 2011;11:493-501.
24. Tian H, Callahan CA, DuPree KJ, Darbonne WC, Ahn CP, Scales SJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A 2009;106:4254-9.
25. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007;13:944-51.
26. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008;455:406-10.
27. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
28. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements acttorestrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014;25:735-47.
29. Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (Vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res 2014;20:5937-45.
30. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res 2013;19:258-67.
31. Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, et al. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res 2012;18:6509-18.
32. Reifenberger J, Wolter M, Weber RG, Megahed M, Ruzicka T, Lichter P, et al. Missense mutations in SMOH in sporadicbasal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998;58:1798-803.
33. Smith MJ, Beetz C, Williams SG, Bhaskar SS, O'Sullivan J, Anderson B, et al. Germline mutations in SUFU cause gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 2014;32:4155-61.
34. Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31:306-10.
35. Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, Rowitch D, et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res 2006;66:10171-8.
36. Corcoran RB, Scott MP. A mouse model for medulloblastoma and basal cell nevus syndrome. J Neurooncol 2001;53:307-18.
37. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 2002;16:2743-8.
38. Tremblay MR, Nevalainen M, Nair SJ, Porter JR, Castro AC, Behnke ML, et al. Semisynthetic cyclopamine analogues as potent and orally bioavail-able hedgehog pathway antagonists. J Med Chem 2008;51:6646-9.
39. Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1()p53(-/-) mice. Cancer Cell 2004; 6:229-40.
40. Robarge KD, Brunton SA, Castanedo GM, Cui Y, Dina MS, Goldsmith R, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009;19:5576-81.
41. Sasai K, Romer JT, Lee Y, Finkelstein D, Fuller C, McKinnon PJ, et al. Shh pathway activity is down-regulated in cultured medulloblastoma cells: implications for preclinical studies. Cancer Res 2006;66:4215-22.
42. Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, et al. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res 2011;17:4682-92.
43. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) inpatients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:2502-11.
44. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366:2171-9.
45. Dreno B, Basset-Seguin N, Caro I, Yue H, Schadendorf D. Clinical benefit assessment of vismodegib therapy in patients with advanced Basal cell carcinoma. Oncologist 2014;19:790-6.
46. Sekulic A, Hainsworth JD, Lewis KD, Oro AE, Gesierich A, Mortier L, et al. Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression. J Clin Oncol 32:5s, 2014 (suppl; abstr 9081).
47. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long term safety and Efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18 months update of the pivotal ERIVANCE BCC study. J Clin Oncol 31:15s, 2014 (suppl; abstr 9037).
48. Grob JJ, Kunstfeld R, Dreno B, Jouary T, Mortier L, Basset-Seguin N, et al. Vismodegib a hedgehog pathway inhibitor (HPI) in advanced basal cell carcinoma (aBCC); Stevie study interim analysis in 300 patients. J Clin Oncol 31, 2013 (suppl; abstr 9036).
49. Lewis KD, Sekulic A, Hauschild A, Migden MR, Oro AE, et al. Vismodegib in thetreatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phaseII and phase I studies.J Clin Oncol 2014;32:5s (suppl; abstr 9012).
50. Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. JAMA Derma-tol 2014;70:60-9.
51. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366:2180-8.
52. Goldberg LH, Landau JM, Moody MN, Kazakevich N, Holzer AM, Myers A. Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449. Arch Dermatol 2011;147:839-41.
53. Ally MS, Aasi S, Wysong A, Teng C, Anderson E, Bailey-Healy I, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadju-vant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol 2014;71:904-11.
54. Zhu GA, Sundram U, Chang AL. Two different scenarios of squamous cell carcinoma within advanced basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. JAMA Dermatol 2014;150:970-3.
55. Orouji A, Goerdt S, Utikal J, Leverkus M. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma. Br J Dermatol 2014;171: 431-3.
56. Aasi S, Silkiss R, Tang JY, Wysong A, Liu A, Epstein E, et al. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol 2013;149:242-3.
57. Siu LL, Pappadopoulos K, Alberts SR, Kirchoff-Ross R, Vakkalagadda B, Lang L, et al. A first in human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139) in subjects with advanced or metastatic tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 2501).
58. Wang C, Wu H, Katritch V, Han GW, Huang XP, Liu W, et al. Structure of the human smoothened receptor bound to an antitumour agent. Nature 2013;497:338-43.
59. Wagner AJ, Messersmith WA, Shaik MN, Li S, Zheng X, McLachlan KR, et al. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2014 Nov 11. [Epub ahead of print].
60. Peukert S, He F, Dai M, Zhang R, Sun Y, Miller-Moslin K, et al. Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. Chem Med Chem 2013;8:1261-5.
61. Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 2014;20:1900-9.
62. Midgen MR, Gumisnki AD, Gutzmer R, Dirix LY, Lewis KD, Combemale P, et al. Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC). J Clin Oncol 32:5s, 2014 (suppl; abstr 9009a^).
63. Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013;23:23-34.
64. Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010;17:388-99.
65. Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 2014;32:745-51.
66. Tang T, Tang JY, Li D, Reich M, Callahan CA, Fu L, et al. Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res 2011;17:3378-87.
67. Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011;131:1735-44.
68. Kool M, Jones DT, Jager N, Northcott PA, Pugh TJ, Hovestadt V, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 2014;25: 393-405.
69. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, et al. Smoothened mutation confers resistancetoaHedgehogpathway inhibitor in medulloblastoma. Science 2009;326:572-4.
70. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361:1173-8.
71. Chang AL, Oro AE. Initial assessment of tumor regrowth after vismo-degib in advanced Basal cell carcinoma. Arch Dermatol 2012;148: 1324-5.
72. Brinkhuizen T, Reinders MG, van Geel M, Hendriksen AJ, Paulussen AD, Winnepenninckx VJ, et al. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol 2014;71: 1005-8.
73. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010;2:51ra70.
74. Metcalfe C, Alicke B, Crow A, Lamoureux M, Dijkgraaf GJ, Peale F, et al. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition. Cancer Res 2013;73:7034-42.
75. Chang AS, Oro A. Open-label pilot study of LDE225 in advanced basal cell carcinoma patients who have been treated previously with a non-LDE225 Smoothened inhibitor. J Invest Dermatol 134:S101, 2014 (suppl; abstr 580).
76. Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med 2014;20:732-40.